H1N1 疫苗市场 - 全球产业规模、份额、趋势、机会和预测，按给药途径、品牌类型、配销通路、地区和竞争细分，2020-2030 年预测

2024 年全球 H1N1 疫苗市值为 99.1 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 4.23%。全球 H1N1 疫苗市场是医疗保健产业的重要组成部分，主要着重于预防和控制 H1N1 流感病毒（俗称猪流感）的传播。全球 H1N1 疫苗市场受到多种因素推动，主要是流感疫情的盛行率上升和人们对疫苗接种计划的认识不断提高。世界各国政府和医疗保健组织正在投资免疫计划，以预防季节性流感和大流行性流感，推动了对 H1N1 疫苗的需求。老年人口的不断增长，使得 H1N1 感染者更容易出现严重的併发症，这进一步促进了市场的成长。例如，根据美国疾病管制与预防中心在 2023 年 10 月发布的估计，全球季节性流感病例将接近 10 亿例，其中约 300 万至 500 万例为重症。国家和全球层面加强监测力度和政府对疫苗接种的强力支持（重点监测分发、供应和管理）是推动市场成长的关键因素。

疫苗开发的进步，包括重组疫苗和佐剂疫苗，提高了疫苗功效并推动了疫苗的采用。新的H1N1病毒株的出现需要疫苗的不断更新，从而支持市场扩张。不断增加的研发活动、世界卫生组织和疾病预防控制中心等全球卫生组织的资助以及製药公司之间的策略合作促进了疫苗的快速开发和分发。 COVID-19 疫情提高了民众对呼吸道感染的认识，并加强了整体疫苗基础设施。政府扩大对高风险族群流感疫苗接种的要求，加上优惠的报销政策，进一步刺激了市场成长。疫苗生产的技术进步，包括基于细胞和 mRNA 平台，提高了效率和可扩展性。因此，对提供更广泛流感保护的联合疫苗的需求不断增长，预计将在未来几年推动创新和市场扩张。

主要市场驱动因素

疫情防范与意识

主要市场挑战

病毒突变和进化

主要市场趋势

通用流感疫苗

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球 H1N1 疫苗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依给药途径分类（皮内疫苗、肌肉注射疫苗、鼻内疫苗）
  • 依品牌类型（Agripal、Fiuarix、Influgen、Influvac、Nasovac、Vaxigrip）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司分类（2024）
• 产品市场图
  • 依给药途径
  • 按品牌类型
  • 按配销通路
  • 按地区

第 6 章：北美 H1N1 疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲 H1N1 疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 法国
  • 义大利
  • 西班牙

第 8 章：亚太地区 H1N1 疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 日本
  • 印度
  • 澳洲
  • 韩国

第 9 章：南美洲 H1N1 疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲 H1N1 疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 科威特

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 合併与收购
• 产品发布

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• AstraZeneca PLC

。 14.1.1.业务概览

• 产品供应
• 最新动态
• 财务状况（据报告）
• 主要人员
• SWOT 分析
• 赛诺菲巴斯德默沙东
• 葛兰素史克公司
• 雅培实验室公司
• 加拿大行动通讯有限公司
• 辉瑞公司
• CPL Biologicals Pvt Ltd
• 田边三菱製药公司
• 科兴生物科技股份有限公司
• Zydus 生命科学有限公司

第 15 章：策略建议

第16章调查会社について・免责事项

Global H1N1 Vaccines Market was valued at USD 9.91 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.23% through 2030. The global H1N1 vaccines market is a crucial component of the healthcare industry, primarily focused on preventing and controlling the spread of the H1N1 influenza virus, commonly known as swine flu. The global H1N1 vaccines market is driven by multiple factors, primarily the rising prevalence of influenza outbreaks and the increasing awareness of vaccination programs. Governments and healthcare organizations worldwide are investing in immunization initiatives to prevent seasonal and pandemic influenza, fueling demand for H1N1 vaccines. The growing elderly population, which is more susceptible to severe complications from H1N1 infections, further boosts market growth. For instance, according to CDC estimates published in October 2023, nearly one billion cases of seasonal influenza occur worldwide, with approximately 3-5 million classified as severe. The increased surveillance efforts and strong government support for vaccination at both national and global levels-focusing on monitoring distribution, supply, and administration-are key factors driving market growth.

Advancements in vaccine development, including recombinant and adjuvanted vaccines, enhance efficacy and drive adoption. The emergence of new H1N1 virus strains necessitates continuous vaccine updates, supporting market expansion. Increasing R&D activities, funding from global health organizations such as the WHO and CDC, and strategic collaborations among pharmaceutical companies contribute to the rapid development and distribution of vaccines. The COVID-19 pandemic has heightened public awareness of respiratory infections, strengthening the overall vaccine infrastructure. Expanding government mandates for influenza vaccination in high-risk groups, coupled with favorable reimbursement policies, further stimulate market growth. Technological advancements in vaccine production, including cell-based and mRNA platforms, offer improved efficiency and scalability. Therefore, the rising demand for combination vaccines that provide broader influenza protection is expected to drive innovation and market expansion in the coming years.

Key Market Drivers

Pandemic Preparedness and Awareness

Pandemic preparedness and awareness play a crucial role in driving the growth of the global H1N1 vaccines market. Governments, health organizations, and pharmaceutical companies have intensified efforts to strengthen pandemic response strategies, ensuring rapid vaccine development, stockpiling, and distribution. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) continue to promote global surveillance programs, early detection systems, and public awareness campaigns, increasing the demand for H1N1 vaccines. The COVID-19 pandemic has further underscored the importance of robust vaccination programs, leading to improved healthcare infrastructure and vaccine supply chains. Growing public awareness about the risks of influenza pandemics has encouraged higher vaccination rates, particularly among vulnerable populations such as the elderly, pregnant women, and immunocompromised individuals. Governments worldwide are implementing mandatory vaccination policies for healthcare workers and high-risk groups, boosting market expansion. The pandemic preparedness initiatives have led to significant investments in vaccine research, resulting in the development of more effective and rapidly deployable H1N1 vaccines, including cell-based and mRNA-based formulations. Increased collaboration between public and private sectors has accelerated vaccine accessibility, further driving market growth. As global preparedness measures continue to evolve, the demand for H1N1 vaccines is expected to rise, ensuring better pandemic resilience. According to the World Health Organization (WHO), seasonal influenza causes approximately 3 to 5 million cases of severe illness and between 290,000 to 650,000 respiratory-related deaths annually. In industrialized countries, the majority of influenza-related deaths occur in individuals over 65 years old. Seasonal influenza can lead to a wide range of health outcomes, from mild illness to severe complications and even death.

Key Market Challenges

Virus Mutations and Evolution

Perhaps the most significant challenge in the H1N1 vaccines market is the constant evolution of the virus. H1N1 influenza strains mutate regularly, making it necessary to update vaccine formulations to match the currently circulating strains. This requires ongoing research, surveillance, and timely adjustments in vaccine production, driving the need for advanced manufacturing technologies and robust global monitoring systems. Governments and health organizations, such as the WHO and CDC, play a crucial role in identifying dominant strains and recommending vaccine updates, ensuring continued market demand. The pharmaceutical companies invest heavily in innovative vaccine platforms, such as mRNA and cell-based technologies, to enable faster production and adaptability to viral mutations. The unpredictable nature of influenza outbreaks necessitates strategic vaccine stockpiling and rapid distribution systems, further fueling market growth. As global health preparedness efforts intensify, the demand for adaptable and effective H1N1 vaccines continues to rise, supporting the expansion of the market.

Key Market Trends

Universal Influenza Vaccines

One of the most promising trends driving the growth of the global H1N1 vaccines market is the development of universal influenza vaccines. Unlike traditional seasonal flu vaccines, which require frequent updates to match circulating strains, universal vaccines aim to provide long-lasting immunity against multiple influenza subtypes, including H1N1. These vaccines target conserved regions of the virus, such as hemagglutinin stalk domains and internal viral proteins, which undergo fewer mutations compared to surface antigens. By inducing broader immune responses, universal vaccines could significantly reduce the burden of annual vaccinations and enhance pandemic preparedness. Pharmaceutical companies and research institutions are actively investing in advanced vaccine platforms, including mRNA, viral vector, and nanoparticle-based approaches, to accelerate universal vaccine development. The growing support from governments and global health organizations is further driving clinical trials and regulatory approvals. A successful universal influenza vaccine could streamline vaccine manufacturing, reducing production costs and distribution challenges. This breakthrough would be particularly beneficial for low- and middle-income countries with limited healthcare resources, improving global access to influenza prevention. As research progresses and technological advancements continue, universal influenza vaccines have the potential to transform the H1N1 vaccines market, offering a more efficient and sustainable approach to combating influenza outbreaks worldwide.

Key Market Players

• AstraZeneca PLC
• Sanofi Pasteur MSD AG
• GSK PLC
• Abbott Laboratories Inc
• CSL Ltd
• Pfizer Inc
• CPL Biologicals Pvt Ltd
• Mitsubishi Tanabe Pharma Corp
• Sinovac Biotech Co Ltd
• Zydus Lifesciences Ltd

Report Scope:

In this report, the Global H1N1 Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

H1N1 Vaccines Market, By Route of Administration:

• Intradermal Vaccines
• Intramuscular Vaccines
• Intranasal Vaccines

H1N1 Vaccines Market, By Type of Brand:

• Agripal
• Fiuarix
• Influgen
• Influvac
• Nasovac
• Vaxigrip

H1N1 Vaccines Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

H1N1 Vaccines Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global H1N1 Vaccines Market.

Available Customizations:

Global H1N1 Vaccines market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global H1N1 Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 5.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Route of Administration
  • 5.3.2. By Type of Brand
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America H1N1 Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 6.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States H1N1 Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Type of Brand
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada H1N1 Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Type of Brand
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico H1N1 Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Type of Brand
      • 6.3.3.2.3. By Distribution Channel

7. Europe H1N1 Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 7.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany H1N1 Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Type of Brand
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom H1N1 Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Type of Brand
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. France H1N1 Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Type of Brand
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy H1N1 Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Type of Brand
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain H1N1 Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Type of Brand
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific H1N1 Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 8.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China H1N1 Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Type of Brand
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Japan H1N1 Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Type of Brand
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. India H1N1 Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Type of Brand
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Australia H1N1 Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Type of Brand
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. South Korea H1N1 Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Type of Brand
      • 8.3.5.2.3. By Distribution Channel

9. South America H1N1 Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 9.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil H1N1 Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Type of Brand
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina H1N1 Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Type of Brand
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia H1N1 Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Type of Brand
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa H1N1 Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 10.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa H1N1 Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Type of Brand
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia H1N1 Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Type of Brand
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE H1N1 Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Type of Brand
      • 10.3.3.2.3. By Distribution Channel
  • 10.3.4. Kuwait H1N1 Vaccines Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Route of Administration
      • 10.3.4.2.2. By Type of Brand
      • 10.3.4.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. AstraZeneca PLC

. 14.1.1. Business Overview

• 14.1.2. Product Offerings
• 14.1.3. Recent Developments
• 14.1.4. Financials (As Reported)
• 14.1.5. Key Personnel
• 14.1.6. SWOT Analysis
• 14.2. Sanofi Pasteur MSD AG
• 14.3. GSK PLC
• 14.4. Abbott Laboratories Inc
• 14.5. CSL Ltd
• 14.6. Pfizer Inc
• 14.7. CPL Biologicals Pvt Ltd
• 14.8. Mitsubishi Tanabe Pharma Corp
• 14.9. Sinovac Biotech Co Ltd
• 14.10. Zydus Lifesciences Ltd

15. Strategic Recommendations

16. About Us & Disclaimer